Method of mutation analysis may contribute to discrepancies in reports of V599EBRAF mutation frequencies in melanocytic neoplasms [1]

Journal of Investigative Dermatology

Volumn 123, Issue 5, 2004, Pages 990-992

  Miller, Christopher J ^a   Cheung, Mitchell ^a   Sharma, Arati ^a   Clarke, Loren ^a   Helm, Klaus ^a   Mauger, David ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE SPECIFIC POLYMERASE CHAIN REACTION; BRAF GENE; CARCINOGENESIS; DIRECT FLUORESCENCE SEQUENCING; FLUORESCENCE ANALYSIS; GENE; HUMAN; LETTER; MELANOCYTIC NEOPLASM; MELANOMA; MUTATION RATE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TECHNIQUE; TITRIMETRY;

EID: 6344275003     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23468.x     Document Type: Letter

References (19)

1. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H: Cutaneous melanomas associated with nevi. Arch Dermatol 139:1620-1624, 2003
2. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 63:5669-5673, 2003
3. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
4. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 63:3883-3885, 2003
5. Gorden A, Osman I, Gai W, et al: Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63:3955-3957, 2003
6. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198-5202, 2003
7. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K: BRAF mutations in metastatic melanoma: A possible association with clinical outcome. Clin Cancer Res 9:3362-3368, 2003
8. Kumar R, Angelini S, Hemminki K: Activating BRAF and N-Ras mutations in sporadic primary melanomas: An inverse association with allelic loss on chromosome 9. Oncogene 22:9217-9224, 2003
9. Kumar R, Angelini S, Snellman E, Hemminki K: BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 122:342-348, 2004
10. Lang J, Boxer M, MacKie R: Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 21:327-330, 2003
11. Maldonado JL, Fridlyand J, Patel H, et al: Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-1890, 2003
12. Markoulatos P, Siafakas N, Moncany M: Multiplex polymerase chain reaction: A practical approach. J Clin Lab Anal 16:47-51, 2002
13. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003
14. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19:6594-6599, 2000
15. Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL: CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 64:1595-1599, 2004
16. Tsao H, Goel V, Wu H, Yang G, Haluska FG: Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122:337-341, 2004
17. Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95-98, 2003
18. Uribe P, Wistuba II, Gonzalez S: BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-370, 2003
19. Yazdi AS, Palmedo G, Flaig MJ, et al: Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121:1160-1162, 2003